When done correctly, the method turns complexity into clarity and risk into foresight, our guest columnist writes.

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in ...

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) – Late-breaking Phase III FENtrepid ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayed In response to an FDA request, Sanofi has submitted an ...

The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

When budgets start to tighten, most leaders double down on efficiency—but the difference between teams that thrive and teams that stall isn’t spending. It’s synchronization. While working across SaaS, ...

- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide - - In a pivotal PPMS study ...

About 1 million people in the U.S. live with multiple sclerosis, a chronic autoimmune disease that inflames the nervous system and scrambles communication between the brain and body. MS, for which ...

More than most regions in the world, Southeast Asia has found itself in the middle of the intensifying U.S.-Chinese rivalry. Most major countries in other parts of Asia are already spoken for: ...